<div id="readability-page-1"><p>Twelve Points Wealth Management LLC boosted its holdings in shares of  The Chemours Company (NYSE:CC - Free Report) by 42.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 78,325 shares of the specialty chemicals company's stock after buying an additional 23,490 shares during the period. Twelve Points Wealth Management LLC owned approximately 0.05% of Chemours worth $1,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders</li></ul><p>Other hedge funds also recently added to or reduced their stakes in the company. KBC Group NV grew its holdings in shares of  Chemours by 19.5% during the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock valued at $91,000 after buying an additional 728 shares during the last quarter.  Blue Trust Inc. grew its stake in  Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 731 shares during the last quarter.  GAMMA Investing LLC grew its stake in  Chemours by 99.7% during the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 765 shares during the last quarter.  State of Alaska Department of Revenue increased its holdings in shares of  Chemours by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company's stock valued at $349,000 after purchasing an additional 1,175 shares during the period.  Finally, Signaturefd LLC raised its stake in shares of  Chemours by 163.7% in the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after purchasing an additional 1,216 shares during the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds. </p><h2>Insider Buying and Selling</h2><p>In other news, SVP Alvenia Scarborough sold 7,500 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the sale, the senior vice president now owns 16,645 shares of the company's stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.47% of the stock is currently owned by insiders. </p><h2>Analyst Ratings Changes</h2><ul><li>Carnival: 4 Reasons to Set Sail in This Stock in 2025 </li></ul><p>CC has been the topic of several research reports. BMO Capital Markets increased their price target on shares of Chemours from $30.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, October 7th. Barclays increased their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 5th. The Goldman Sachs Group decreased their target price on shares of Chemours from $24.00 to $21.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, January 7th. Mizuho cut their price target on Chemours from $22.00 to $21.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, January 7th. Finally, Truist Financial began coverage on Chemours in a research note on Tuesday. They set a &#34;buy&#34; rating and a $27.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and four have issued  a buy rating to the stock. Based on data from MarketBeat, Chemours presently has an average rating of &#34;Hold&#34; and an average target price of $24.11.</p><p><b>Get Our Latest Analysis on CC</b></p><h2>Chemours Trading Down 1.8 %</h2><ul><li>Breaking the Mold: 3 Non-Tech Stocks Ready to Surge in 2025</li></ul><p>Shares of CC stock opened at $18.76 on Wednesday. The Chemours Company has a 1-year low of $15.10 and a 1-year high of $31.76. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.83. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The stock has a 50 day simple moving average of $19.18 and a 200-day simple moving average of $19.55. </p><p>Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.08. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company's revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share.  On average, equities research analysts expect that  The Chemours Company will post 1.19 EPS for the current fiscal year. </p><h2>Chemours Company Profile</h2> (Free Report)<p>The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Chemours</li><li>Do ETFs Pay Dividends? What You Need to Know</li><li>Apple Swings to Outperformer: Is It a Buy Ahead of Earnings?</li><li>3 Tickers Leading a Meme Stock Revival</li><li>American Airlines: Industry Headwinds or Internal Flaws?</li><li>What Are Dividend Contenders? Investing in Dividend Contenders</li><li>3 Trucking Stocks Leading the Way in Market Momentum</li></ul><p><strong>Want to see what other hedge funds are holding CC?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUND"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Chemours Right Now?</h2><p>Before you consider Chemours, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.</p><p>While Chemours currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Twelve Points Wealth Management LLC increased its stake in The Chemours Company (NYSE:CC) by 42.8% in Q4, owning 78,325 shares valued at $1.32 million. Other institutional investors also adjusted their holdings. Insider Alvenia Scarborough sold 7,500 shares, reducing ownership by 31.06%. Analysts have mixed ratings, with price targets ranging from $21 to $32. Chemours shares opened at $18.76, with a market cap of $2.80 billion and a P/E ratio of 37.51.</p>

The Chemours Company (NYSE:CC) Shares Purchased by Twelve Points Wealth Management LLC